City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  108  Clinical trial(s) found  (Page 1 of 5 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 17168

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  Open-Label, Dose Escalation/Expansion Phase 1B Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, with or without Rituximab, in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

COH Protocol Number: 17150 ClinicalTrials.gov Number: NCT03170960

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

COH Protocol Number: 17138 ClinicalTrials.gov Number: NCT03145181

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody® Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 17112

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  An Open Label, Phase 1b, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PU-H71 in Combination with Standard of Care Chemotherapy in Adults with Metastatic Pancreatic Cancer

COH Protocol Number: 17109 ClinicalTrials.gov Number: NCT03104699

Principal Investigator: Edward Wang, MD
Sponsor: Industrial

Title:  A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

COH Protocol Number: 17095 ClinicalTrials.gov Number: NCT02539719

Principal Investigator: Mihaela Cristea, MD
Sponsor: Industrial

Title:  A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects with Platinum-Resistant/Refractory Ovarian Cancer

COH Protocol Number: 17080 ClinicalTrials.gov Number: NCT03150329

Principal Investigator: Alex Herrera, MD
Sponsor: Institutional

Title:  A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

COH Protocol Number: 17068 ClinicalTrials.gov Number: NCT03061201

Principal Investigator: Nadia Ewing, MD
Sponsor: Industrial

Title:  A Phase 1/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 (Recombinant AAV2/6 Human Factor 8 Gene Therapy) in Adult Subjects with Severe Hemophilia A

COH Protocol Number: 17066 ClinicalTrials.gov Number: NCT03145909

Principal Investigator: George Somlo, MD
Sponsor: Industrial

Title:  A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects with Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

COH Protocol Number: 17008 ClinicalTrials.gov Number: NCT03119467

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Multi-Center, Open label, Dose Escalation, Phase I/Ib Study to Evaluate the Safety and Efficacy of RP4010, a Calcium Release Activated Calcium (CRAC) Channel Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

COH Protocol Number: 17007 ClinicalTrials.gov Number: NCT03068351

Principal Investigator: Myo Htut, MD
Sponsor: Industrial

Title:  Open-Label, Multicenter, Dose-escalation/Expansion Phase IB Study to Evaluate Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients with Advanced Multiple Myeloma

COH Protocol Number: 16464 ClinicalTrials.gov Number: NCT03100877

Principal Investigator: Amrita Krishnan, MD
Sponsor: Institutional

Title:  Phase I-II Single Cycle Melphalan/Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) Followed by Maintenance in Patients with High-Risk Myeloma and/or Poor Response to Induction Therapy within 12 Months of Diagnosis

COH Protocol Number: 16452 ClinicalTrials.gov Number: NCT02589522

Principal Investigator: Sagus Sampath, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-90, NCI#9952: Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

COH Protocol Number: 16425 ClinicalTrials.gov Number: NCT02391480

Principal Investigator: Ibrahim Aldoss, MD
Sponsor: Industrial

Title:  A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects with Advanced Cancer

COH Protocol Number: 16421 ClinicalTrials.gov Number: NCT02295059

Principal Investigator: Victoria Seewaldt, MD
Sponsor: Institutional

Title:  Omega-3 Fatty Acids and ERPR(-) and HER-2/neu(+) Breast Cancer Prevention

COH Protocol Number: 16414 ClinicalTrials.gov Number: NCT03013933

Principal Investigator: Robert Chen, MD
Sponsor: Institutional

Title:  A Phase I Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma

COH Protocol Number: 16408 ClinicalTrials.gov Number: NCT02959437

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non–Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer

COH Protocol Number: 16368 ClinicalTrials.gov Number: NCT02953509

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma

COH Protocol Number: 16346 ClinicalTrials.gov Number: NCT02568553

Principal Investigator: Jasmine Zain, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-79, NCI#9924: A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)

COH Protocol Number: 16318 ClinicalTrials.gov Number: NCT02760485

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

COH Protocol Number: 16316 ClinicalTrials.gov Number: NCT02951156

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  Phase 1b/Phase 3 Multicenter Study of Avelumab (MSB0010718c) in Combination Regimens that Include an Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DBCL)

COH Protocol Number: 16305 ClinicalTrials.gov Number: NCT02954796

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  Phase 1 Study of SGN-CD352A in Patients with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 16294 ClinicalTrials.gov Number: NCT02996825

Principal Investigator: Mihaela Cristea, MD
Sponsor: Institutional

Title:  A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients with FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)

COH Protocol Number: 16280 ClinicalTrials.gov Number: NCT02665650

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination with Pembrolizumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

COH Protocol Number: 16279 ClinicalTrials.gov Number: NCT02926833

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.